Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
DECIPHER LABS TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DECIPHER LABS Mar-23 |
TEVA PHARMA Dec-13 |
DECIPHER LABS/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 63 | 3,479 | - | |
Low | Rs | 14 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 45.1 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | -2.7 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | -2.2 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.18 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 23.0 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 10.10 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.9 | 1.6 | 52.4% | |
Avg P/E ratio | x | -14.5 | 26.1 | -55.7% | |
P/CF ratio (eoy) | x | -17.3 | 11.4 | -151.9% | |
Price / Book Value ratio | x | 1.7 | 1.5 | 114.4% | |
Dividend payout | % | 0 | 87.5 | -0.0% | |
Avg Mkt Cap | Rs m | 389 | 2,756,220 | 0.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 412 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 456 | 1,692,969 | 0.0% | |
Other income | Rs m | 74 | 0 | - | |
Total revenues | Rs m | 529 | 1,692,969 | 0.0% | |
Gross profit | Rs m | -106 | 463,620 | -0.0% | |
Depreciation | Rs m | 4 | 136,844 | 0.0% | |
Interest | Rs m | 5 | 33,253 | 0.0% | |
Profit before tax | Rs m | -42 | 293,523 | -0.0% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | -15 | -3,584 | 0.4% | |
Profit after tax | Rs m | -27 | 105,758 | -0.0% | |
Gross profit margin | % | -23.3 | 27.4 | -85.1% | |
Effective tax rate | % | 35.5 | -1.2 | -2,908.8% | |
Net profit margin | % | -5.9 | 6.2 | -94.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 201 | 1,143,425 | 0.0% | |
Current liabilities | Rs m | 50 | 997,163 | 0.0% | |
Net working cap to sales | % | 33.2 | 8.6 | 384.2% | |
Current ratio | x | 4.1 | 1.1 | 353.4% | |
Inventory Days | Days | 30 | 91 | 33.2% | |
Debtors Days | Days | 789 | 96 | 822.9% | |
Net fixed assets | Rs m | 71 | 552,961 | 0.0% | |
Share capital | Rs m | 101 | 4,167 | 2.4% | |
Net worth | Rs m | 232 | 1,880,567 | 0.0% | |
Long term debt | Rs m | 0 | 865,653 | 0.0% | |
Total assets | Rs m | 272 | 3,868,976 | 0.0% | |
Interest coverage | x | -7.6 | 9.8 | -77.6% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 1.7 | 0.4 | 383.5% | |
Return on assets | % | -8.1 | 3.6 | -225.5% | |
Return on equity | % | -11.6 | 5.6 | -205.5% | |
Return on capital | % | -15.8 | 4.9 | -321.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -16 | 269,772 | -0.0% | |
From Investments | Rs m | -43 | -95,591 | 0.0% | |
From Financial Activity | Rs m | -22 | -323,609 | 0.0% | |
Net Cashflow | Rs m | -80 | -149,429 | 0.1% |
Compare DECIPHER LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare DECIPHER LABS With: BROOKS LAB AARTI DRUGS S.S.ORGANICS AURO LAB. PROCTER & GAMBLE HEALTH
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.